US8207233B1 - Methods for treating diabetic foot ulcers - Google Patents

Methods for treating diabetic foot ulcers Download PDF

Info

Publication number
US8207233B1
US8207233B1 US13/364,061 US201213364061A US8207233B1 US 8207233 B1 US8207233 B1 US 8207233B1 US 201213364061 A US201213364061 A US 201213364061A US 8207233 B1 US8207233 B1 US 8207233B1
Authority
US
United States
Prior art keywords
weight
peptide
ulcer
diabetic foot
basis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US13/364,061
Other languages
English (en)
Inventor
Kathleen E. Rodgers
Gere S. diZerega
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45571822&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US8207233(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Southern California USC filed Critical University of Southern California USC
Priority to US13/364,061 priority Critical patent/US8207233B1/en
Priority to US13/441,653 priority patent/US8207234B1/en
Priority to US13/467,253 priority patent/US8536231B2/en
Application granted granted Critical
Publication of US8207233B1 publication Critical patent/US8207233B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • Diabetes is common, disabling and deadly. In the U.S., diabetes has reached epidemic proportions. According to the American Diabetes Association, about 24 million people (8% of the total U.S. population) have diabetes, and nearly two million new cases are diagnosed in people aged 20 years or older each year. If current trends continue, 1 in 3 Americans will develop diabetes at some point in their lifetime, and those with diabetes will lose, on average, 10-15 years of life expectancy. Importantly, up to 25% of people with diabetes will develop a diabetic foot ulcer, resulting in 3 million diabetic foot ulcers annually in the U.S. alone. More than half of all foot ulcers will become infected, thus requiring hospitalization, and 1 in 5 will require an amputation that carries a high risk of mortality.
  • the present invention provides methods for treating diabetic foot ulcers, comprising administering to a human patient suffering from a diabetic foot ulcer an amount of a peptide of at least 5 contiguous amino acids of Nle3 A(1-7), or salt thereof, effective to treat the diabetic foot ulcer.
  • the peptide comprises Asp-Arg-Nle-Tyr-Ile-His-Pro (SEQ ID NO:1), or salt thereof.
  • the peptide consists of Asp-Arg-Nle-Tyr-Ile-His-Pro (SEQ ID NO:1), or salt thereof.
  • the diabetic foot ulcer is one caused, at least in part, by neuropathy and resulting pressure; the diabetic foot ulcer comprises one or more calluses; and the diabetic foot ulcer is a chronic ulcer. In a further embodiment, the chronic foot ulcer has not responded to any other treatment.
  • the peptide is administered topically. In a further embodiment, the peptide is administered as a topical formulation forming a continuous film covering the entire area of the diabetic ulcer. In a still further embodiment, the peptide is administered in a hydrogel formulation. In another embodiment, the peptide is administered at a concentration of about 0.03% to about 1% on a weight (mg)/volume (ml) basis, or on a weight/weight (mg) basis. In a further embodiment, the peptide is administered in a gel formulation that about 0.5% to about 4% hydroxyethyl cellulose (HEC) on a weight (mg)/volume (ml) basis, or on a weight/weight (mg) basis.
  • HEC hydroxyethyl cellulose
  • the present invention provides pharmaceutical formulations, comprising:
  • the peptide is present at a concentration of about 0.03% to about 1% on a weight (mg)/volume (ml) basis, or on a weight/weight (mg) basis.
  • the peptide comprises Asp-Arg-Nle-Tyr-Ile-His-Pro (SEQ ID NO:1), or salt thereof. In another embodiment, the peptide consists of Asp-Arg-Nle-Tyr-Ile-His-Pro (SEQ ID NO:1), or salt thereof.
  • the pharmaceutical formulation comprises about 1% to about 3% HEC on a weight (mg)/volume (ml) basis, or on a weight/weight (mg) basis. In a still further embodiment, the pharmaceutical formulation comprises about 2% HEC on a weight (mg)/volume (ml) basis, or on a weight/weight (mg) basis. In another embodiment, the formulation comprises a hydrogel formulation. All embodiments of the second aspect of the invention can be combined unless the context dictates otherwise.
  • FIG. 1 is a graph showing the ulcers healed by visit in the Per Protocol (PP) patient population taking NorLeu 3 -A(1-7).
  • FIG. 2 is a graph showing the percentage of fully healed ulcers (100% wound closure) in the patient population taking NorLeu 3 -A(1-7) (also referred to as “DSC127”).
  • FIG. 3 is a graph showing the median time to fully healed ulcers (100% wound closure) in the patient population taking NorLeu 3 -A(1-7) (also referred to as “DSC127”).
  • the present invention provides methods for treating diabetic foot ulcers, comprising administering to a human patient suffering from a diabetic foot ulcer an amount of a peptide of at least 5 contiguous amino acids of Nle3 A(1-7), or salt thereof, effective to treat the diabetic foot ulcer.
  • the inventors have demonstrated that the methods of the invention can be used to treat diabetic foot ulcers, and provide substantial improvement over standard therapies.
  • Nle3A(1-7) (or NorLeu 3 -A(1-7); also referred to as “DSC127”) is a peptide consisting of the amino acid sequence Asp-Arg-Nle-Tyr-Ile-His-Pro (SEQ ID NO:1).
  • the peptide administered to the human patient may comprise or consist of Asp-Arg-Nle-Tyr-Ile (SEQ ID NO:2), Asp-Arg-Nle-Tyr-Ile-His (SEQ ID NO:3), or most preferably Asp-Arg-Nle-Tyr-Ile-His-Pro (SEQ ID NO:1), or salts thereof.
  • Nle3A(1-7) or salts thereof may be chemically synthesized or recombinantly expressed, each of which can be accomplished using standard methods in the art.
  • the peptide, or salt thereof is administered at a concentration of about 0.03% to about 1% on a weight (mg)/volume (ml) basis, or on a weight/weight (mg) basis. In various further embodiments, the peptide, or salt thereof, is administered at a concentration of about 0.03% to about 0.75%; about 0.03% to about 0.5%; about 0.03% to about 0.25%; about 0.03% to about 0.1%; about 0.03% to about 0.075%; about 0.03% to about 0.05%; and about 0.03%; all on a weight (mg)/volume (ml) basis, or on a weight/weight (mg) basis.
  • the human patient may be suffering from Type I diabetes or Type II diabetes, and has a foot ulcer, defined as an open wound anywhere on the foot (heel, mid-foot, and forefoot).
  • treating includes
  • the foot ulcer may be caused by any underlying pathology, including but not limited to neuropathy, trauma, deformity, high plantar pressures, callus formation, edema, and peripheral arterial disease.
  • the human diabetic foot ulcer is one caused, at least in part, by neuropathy and resulting pressure (weight bearing on the extremity due to lack of feeling in the foot).
  • neuropathy and resulting pressure weight bearing on the extremity due to lack of feeling in the foot.
  • human diabetic foot ulcers tend to be due to neuropathy and pressure, which differs significantly from, for example, murine acute wounds.
  • the diabetic foot ulcer comprises one or more calluses.
  • the diabetic foot ulcer is a chronic ulcer.
  • a “chronic” foot ulcer is one that has been present for at least 7 days with no reduction in size; preferably at least 14 days; even more preferably, present at least 21 or 28 days with no reduction in size.
  • the chronic foot ulcer has not responded (ie: no reduction in size, area, and/or depth of the foot ulcer; no healing of the foot ulcer) to any other treatment.
  • the peptide or salt thereof may be administered by any suitable route, preferably via topical administration.
  • the methods of the invention can comprise administering a topical formulation as often as deemed appropriate, ie: once per day, twice per day, etc.
  • the methods may further comprise administration of the peptide, or salt thereof for as longed as deemed desirable by an attending physician, for example, until healing of the ulcer.
  • the topical formulation form a continuous film covering the entire area of the ulcer, including the margins.
  • the topical formulation is applied with a thickness of approximately 0.25 to 2 mm; preferably 0.5 to 1.5 mm; preferably about 1 mm in thickness.
  • the topical administration comprises administration in a formulation selected from the group consisting of hydrogels, creams, ointments, pastes, and lotions.
  • the formulations may be applied in any suitable manner, which may include any wound dressings to seal in the formulation deemed appropriate by the human patient or caregiver.
  • Exemplary such dressings include, but are not limited to, semipermeable films, foams, hydrocolloids, and calcium alginate swabs.
  • the methods may further comprise debridement in and around the wound in combination with administration of the peptide and formulations thereof.
  • Debridement of all necrotic, callus, and fibrous tissue is typically carried for treatment of diabetic foot ulcers. Unhealthy tissue is sharply debrided back to bleeding tissue to allow full visualization of the extent of the ulcer and to detect underlying abscesses or sinuses. Any suitable debridement technique can be used, as determined by an attending physician.
  • the wound can then be thoroughly flushed with sterile saline or a non-cytotoxic cleanser following debridement.
  • the topical formulation comprises about 0.5% to about 4% hydroxyethyl cellulose (HEC) on a weight (mg)/volume (ml) basis, or on a weight/weight (mg) basis.
  • the topical formulation may comprise about 1% to about 3% HEC, or about 2% HEC, on a weight (mg)/volume (ml) basis, or on a weight/weight (mg) basis.
  • the peptides, or salt thereof may be administered together with one or more (a) a lyoprotectant; (b) a surfactant; (c) a bulking agent; (d) a tonicity adjusting agent; (e) a stabilizer; (f) a preservative and/or (g) a buffer.
  • the buffer in the pharmaceutical composition is a Tris buffer, a histidine buffer, a phosphate buffer, a citrate buffer or an acetate buffer.
  • the peptides may be administered with a lyoprotectant, e.g. sucrose, sorbitol or trehalose.
  • the peptides may be administered with a preservative e.g.
  • the peptides may be administered with a bulking agent, like glycine.
  • the peptides may be administered with a surfactant e.g., polysorbate-20, polysorbate-40, polysorbate-60, polysorbate-65, polysorbate-80 polysorbate-85, poloxamer-188, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan monooleate, sorbitan trilaurate, sorbitan tristearate, sorbitan trioleaste, or a combination thereof.
  • the peptides may be administered with a tonicity adjusting agent, e.g., a compound that renders the formulation substantially isotonic or isoosmotic with human blood.
  • Exemplary tonicity adjusting agents include sucrose, sorbitol, glycine, methionine, mannitol, dextrose, inositol, sodium chloride, arginine and arginine hydrochloride.
  • the peptides may be administered with a stabilizer, e.g., a molecule which, when combined with the peptide substantially prevents or reduces chemical and/or physical instability of the protein of interest in lyophilized or liquid form.
  • Exemplary stabilizers include sucrose, sorbitol, glycine, inositol, sodium chloride, methionine, arginine, and arginine hydrochloride, paraben, and combinations of methyl paraben and propyl paraben.
  • suitable acids which are capable of forming salts with the peptides include, but are not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, phosphoric acid and the like; and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, anthranilic acid, cinnamic acid, naphthalene sulfonic acid, sulfanilic acid and the like.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, phosphoric acid and the like
  • organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, o
  • Suitable bases capable of forming salts with the peptides include, but are not limited to, inorganic bases such as sodium hydroxide, ammonium hydroxide, potassium hydroxide and the like; and organic bases such as mono-, di- and tri-alkyl and aryl amines (e.g., triethylamine, diisopropyl amine, methyl amine, dimethyl amine and the like) and optionally substituted ethanol-amines (e.g., ethanolamine, diethanolamine and the like).
  • inorganic bases such as sodium hydroxide, ammonium hydroxide, potassium hydroxide and the like
  • organic bases such as mono-, di- and tri-alkyl and aryl amines (e.g., triethylamine, diisopropyl amine, methyl amine, dimethyl amine and the like) and optionally substituted ethanol-amines (e.g., ethanolamine, diethanolamine and the like).
  • the peptides or salts thereof can further be derivatized to provide enhanced half-life, for example, by linking to polyethylene glycol.
  • the peptides or salts thereof may comprise L-amino acids, D-amino acids (which are resistant to L-amino acid-specific proteases in vivo), a combination of D- and L-amino acids, and various “designer” amino acids (e.g., ⁇ -methyl amino acids, C ⁇ -methyl amino acids, and N ⁇ -methyl amino acids, etc.) to convey special properties.
  • the polypeptides may be the sole active agent in the pharmaceutical composition, or the composition may further comprise one or more other active agents suitable treating diabetic foot ulcers, such as antibiotics.
  • the methods may be used in conjunction with other foot ulcer therapies, including but not limited to negative pressure wound therapy, total contact casts, removable cast walkers, half-shoes, becaplermin, infection control, and hyperbaric oxygen therapy.
  • the methods may include any other embodiments as disclosed in the example that follows. Such embodiments may be used in any combination in the methods of the invention, unless the context clearly dictates otherwise.
  • the present invention provides pharmaceutical formulations, comprising:
  • the peptide is present at a concentration of about 0.03% to about 1% on a weight (mg)/volume (ml) basis, or on a weight/weight (mg) basis.
  • the pharmaceutical formulations are demonstrated herein to be particularly effective for treating diabetic foot ulcers, such as chronic diabetic foot ulcers that are not effectively treated using standard therapies.
  • the peptide comprises Asp-Arg-Nle-Tyr-Ile-His-Pro (SEQ ID NO:1), or salt thereof. In another embodiment, the peptide consists of Asp-Arg-Nle-Tyr-Ile-His-Pro (SEQ ID NO:1), or salt thereof.
  • the peptide, or salt thereof is present in the formulation at a concentration of about 0.03% to about 1% on a weight (mg)/volume (ml) basis, or on a weight/weight (mg) basis. In various further embodiments, the peptide, or salt thereof, is present in the formulation at a concentration of about 0.03% to about 0.75%; about 0.03% to about 0.5%;
  • the pharmaceutical formulation comprises about 1% to about 3% HEC on a weight (mg)/volume (ml) basis, or on a weight/weight (mg) basis.
  • These formulations comprising low percentage HEC (ie: 2%) matrices provided a 10-fold increase in peptide release over a 24 hour period from formulations such as those comprising 10% carboxymethylcellulose (CMC), a result that would be unexpected to those of skill in the art.
  • CMC carboxymethylcellulose
  • the pharmaceutical formulation comprises about 2% HEC on a weight (mg)/volume (ml) basis, or on a weight/weight (mg) basis.
  • the formulation comprises a hydrogel formulation.
  • the formulation is topical gel-based formulation selected from the group consisting of hydrogels, creams, ointments, pastes, and lotions.
  • the formulation is administered so as to form a continuous film covering the entire area of the ulcer, including the margins, without running off.
  • the topical formulation is applied with a thickness of approximately 0.25 to 2 mm; preferably 0.5 to 1.5 mm; preferably about 1 mm in thickness.
  • the formulation is applied at approximately 0.075 mL per cm 2 surface area.
  • suitable acids which are capable of forming salts with the peptides include, but are not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, phosphoric acid and the like; and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, anthranilic acid, cinnamic acid, naphthalene sulfonic acid, sulfanilic acid and the like.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, phosphoric acid and the like
  • organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, o
  • Suitable bases capable of forming salts with the peptides include, but are not limited to, inorganic bases such as sodium hydroxide, ammonium hydroxide, potassium hydroxide and the like; and organic bases such as mono-, di- and tri-alkyl and aryl amines (e.g., triethylamine, diisopropyl amine, methyl amine, dimethyl amine and the like) and optionally substituted ethanol-amines (e.g., ethanolamine, diethanolamine and the like).
  • inorganic bases such as sodium hydroxide, ammonium hydroxide, potassium hydroxide and the like
  • organic bases such as mono-, di- and tri-alkyl and aryl amines (e.g., triethylamine, diisopropyl amine, methyl amine, dimethyl amine and the like) and optionally substituted ethanol-amines (e.g., ethanolamine, diethanolamine and the like).
  • the pharmaceutical formulations may further comprise (a) a lyoprotectant; (b) a surfactant; (c) a bulking agent; (d) a tonicity adjusting agent; (e) a stabilizer; (f) a preservative and/or (g) a buffer.
  • the buffer in the pharmaceutical formulations is a Tris buffer, a histidine buffer, a phosphate buffer, a citrate buffer or an acetate buffer.
  • the pharmaceutical formulations may also include a lyoprotectant, e.g. sucrose, sorbitol or trehalose.
  • the pharmaceutical formulations includes a preservative e.g.
  • the pharmaceutical formulations includes a bulking agent, like glycine.
  • the pharmaceutical formulations includes a surfactant e.g., polysorbate-20, polysorbate-40, polysorbate-60, polysorbate-65, polysorbate-80 polysorbate-85, poloxamer-188, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan monooleate, sorbitan trilaurate, sorbitan tristearate, sorbitan trioleaste, or a combination thereof.
  • the pharmaceutical formulations may also include a tonicity adjusting agent, e.g., a compound that renders the formulation substantially isotonic or isoosmotic with human blood.
  • Exemplary tonicity adjusting agents include sucrose, sorbitol, glycine, methionine, mannitol, dextrose, inositol, sodium chloride, arginine and arginine hydrochloride.
  • the pharmaceutical formulations additionally includes a stabilizer, e.g., a molecule which, when combined with a protein of interest substantially prevents or reduces chemical and/or physical instability of the protein of interest in lyophilized or liquid form.
  • Exemplary stabilizers include sucrose, sorbitol, glycine, inositol, sodium chloride, methionine, arginine, and arginine hydrochloride.
  • the peptides or salts thereof can further be derivatized to provide enhanced half-life, for example, by linking to polyethylene glycol.
  • the peptides or salts thereof may comprise L-amino acids, D-amino acids (which are resistant to L-amino acid-specific proteases in vivo), a combination of D- and L-amino acids, and various “designer” amino acids (e.g., ⁇ -methyl amino acids, C ⁇ -methyl amino acids, and N ⁇ -methyl amino acids, etc.) to convey special properties.
  • the peptide may be the sole active agent in the pharmaceutical composition, or the composition may further comprise one or more other active agents suitable for treating diabetic ulcers.
  • formulations may include any other embodiments as disclosed in the example that follows. Such embodiments may be used in any combination in the formulations of the invention, unless the context clearly dictates otherwise.
  • the study was designed as a randomized, parallel-group, double-blind, placebo-controlled, multi-center trial. After 14-days of best-of-care to evaluate ulcer healing and ensure the wounds were chronic, four-weeks of active treatment were then followed by eight weeks of observation and assessment. The study compared the effects of two concentrations of NorLeu 3 -A(1-7) and placebo, measuring both clinical efficacy and safety. Sustained tissue integrity was evaluated for all subjects during a follow-up period lasting 12 weeks after complete wound closure.
  • the four-week treatment period required daily application of the treatment to the wound site.
  • the first application each week was at the clinic and for the remainder of the week the patient self-administered the treatment.
  • Intent-to-Treat (ITT) population all subjects receiving any study medication and from whom any post-baseline data are available: Results show that 54% of the diabetic wounds treated with 0.03% (high dose) of NorLeu 3 -A(1-7) achieved 100% closure in 12 weeks or less, compared with 33% of patients receiving placebo control, and 30% of patients receiving the 0.01% dose (low dose) of NorLeu 3 -A(1-7). Based on odds ratio analysis, patients treated with NorLeu 3 -A(1-7) 0.03% were 2.3 times more likely to have their wounds heal completely as compared to patients treated with placebo/standard of care.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US13/364,061 2011-02-02 2012-02-01 Methods for treating diabetic foot ulcers Active US8207233B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US13/364,061 US8207233B1 (en) 2011-02-02 2012-02-01 Methods for treating diabetic foot ulcers
US13/441,653 US8207234B1 (en) 2011-02-02 2012-04-06 Methods for treating diabetic foot ulcers
US13/467,253 US8536231B2 (en) 2011-02-02 2012-05-09 Methods for treating diabetic foot ulcers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161438780P 2011-02-02 2011-02-02
US13/364,061 US8207233B1 (en) 2011-02-02 2012-02-01 Methods for treating diabetic foot ulcers

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/441,653 Division US8207234B1 (en) 2011-02-02 2012-04-06 Methods for treating diabetic foot ulcers
US13/467,253 Continuation US8536231B2 (en) 2011-02-02 2012-05-09 Methods for treating diabetic foot ulcers

Publications (1)

Publication Number Publication Date
US8207233B1 true US8207233B1 (en) 2012-06-26

Family

ID=45571822

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/364,061 Active US8207233B1 (en) 2011-02-02 2012-02-01 Methods for treating diabetic foot ulcers
US13/441,653 Active US8207234B1 (en) 2011-02-02 2012-04-06 Methods for treating diabetic foot ulcers
US13/467,253 Active US8536231B2 (en) 2011-02-02 2012-05-09 Methods for treating diabetic foot ulcers

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13/441,653 Active US8207234B1 (en) 2011-02-02 2012-04-06 Methods for treating diabetic foot ulcers
US13/467,253 Active US8536231B2 (en) 2011-02-02 2012-05-09 Methods for treating diabetic foot ulcers

Country Status (21)

Country Link
US (3) US8207233B1 (xx)
EP (1) EP2536422B8 (xx)
JP (2) JP5469777B2 (xx)
KR (1) KR101514414B1 (xx)
CN (1) CN102858360B (xx)
AU (1) AU2012212220B2 (xx)
BR (1) BR112013019513A2 (xx)
CA (1) CA2793515C (xx)
CL (1) CL2012002560A1 (xx)
CO (1) CO6592101A2 (xx)
DK (1) DK2536422T3 (xx)
EA (1) EA026440B1 (xx)
ES (1) ES2479765T3 (xx)
HK (1) HK1180213A1 (xx)
MX (1) MX2012010783A (xx)
PE (1) PE20130379A1 (xx)
PL (1) PL2536422T3 (xx)
PT (1) PT2536422E (xx)
SG (1) SG183960A1 (xx)
WO (1) WO2012106427A2 (xx)
ZA (1) ZA201207340B (xx)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120329729A1 (en) * 2011-02-02 2012-12-27 University Of Southern California Methods for treating diabetic foot ulcers
WO2014043693A1 (en) * 2012-09-17 2014-03-20 Tarix Pharmaceuticals Ltd. Oral formulations of angiotensin
US9623084B2 (en) 2013-03-15 2017-04-18 University Of Southern California Methods for treating multiple sclerosis
US9688724B2 (en) 2012-05-14 2017-06-27 University Of Southern California Methods for limiting development of a skin wound
US9732074B2 (en) 2013-03-15 2017-08-15 University Of Southern California Methods, compounds, and compositions for the treatment of angiotensin-related diseases

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9289500B2 (en) * 2013-02-22 2016-03-22 The Regents Of The University Of California Saccharide-peptide hydrogels
US9981011B2 (en) * 2014-03-10 2018-05-29 Rush University Medical Center Methods of promotion of healing of diabetic wounds
WO2016108130A1 (en) * 2014-12-30 2016-07-07 Sun Pharmaceutical Industries Limited Topical pharmaceutical compositions comprising nebivolol for the treatment of diabetic wounds
WO2017100276A1 (en) * 2015-12-08 2017-06-15 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treatment, amelioration, and prevention of diabetes-related skin ulcers
US20240092886A1 (en) * 2019-10-09 2024-03-21 Rush University Medical Center Modulating interleukin-10 signaling to boost healing in diabetic wounds

Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015629A (en) 1989-06-26 1991-05-14 University Of Southern California Tissue repair
US5629292A (en) 1993-09-24 1997-05-13 The University Of Southern California Use of angiotensin III and analogs thereof in tissue repair
US5716935A (en) 1993-09-24 1998-02-10 University Of Southern California Use of antiotensin II analogs in tissue repair
WO1998033813A2 (en) 1997-02-04 1998-08-06 University Of Southern California Method for accelerating healing of thermal injuries
US5834432A (en) 1995-06-06 1998-11-10 The University Of Southern California Use of angiotensin II Type 2 receptor agonists in tissue repair
WO1999031125A1 (en) 1997-12-12 1999-06-24 University Of Southern California Wound healing compositions
WO1999040107A2 (en) 1998-02-09 1999-08-12 University Of Southern California Method of promoting keratinocyte proliferation
US5955430A (en) 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
US6110895A (en) 1996-12-16 2000-08-29 University Of Southern California Method of promoting healing in skin grafts
US6177407B1 (en) 1998-08-13 2001-01-23 University Of Southern California Methods to increase blood flow to ischemic tissue
US6248587B1 (en) 1997-11-26 2001-06-19 University Of Southern Cailfornia Method for promoting mesenchymal stem and lineage-specific cell proliferation
WO2001044270A2 (en) 1999-12-16 2001-06-21 University Of Southern California Methods for treating and preventing diabetic complications by use of angiotensin-related peptides
US6258778B1 (en) 1998-07-13 2001-07-10 University Of Southern California Methods for accelerating bone and cartilage growth and repair
US6335195B1 (en) 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US6455500B1 (en) 1998-03-10 2002-09-24 University Of Southern California Radiation therapy methods
US6475988B1 (en) 1998-05-11 2002-11-05 University Of Southern California Methods to increase white blood cell survival after chemotherapy
US6498138B1 (en) 1998-03-11 2002-12-24 University Of Southern California Method of promoting production of living tissue equivalents
US6730775B1 (en) 1999-03-23 2004-05-04 University Of Southern California Methods for limiting scar and adhesion formation
US6762167B1 (en) 1998-05-11 2004-07-13 University Of Southern California Methods for treating a patient undergoing chemotherapy
US6821953B1 (en) 1999-12-16 2004-11-23 University Of Southern California Methods for treating and preventing damage to mucosal tissue
US6916783B2 (en) 1998-07-13 2005-07-12 University Of Southern California Methods for accelerating bone and cartilage growth and repair
US7173011B2 (en) 2000-11-20 2007-02-06 University Of Southern California Radiation therapy methods
US7338938B2 (en) 1999-05-10 2008-03-04 University Of Southern California Methods for treating a patient undergoing chemotherapy
US20090227507A1 (en) 2008-03-10 2009-09-10 University Of Southern California Angiotensin (1-7) Dosage Forms and Uses Thereof
WO2011120032A1 (en) 2010-03-26 2011-09-29 University Of Southern California Methods for treating combined radiation and thermal injury
WO2012021578A1 (en) 2010-08-10 2012-02-16 University Of Southern California Use of angiotensin- ii (1-7) in cell trans planation and as an agent for preventing/treating norovirus infection

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3062392A (en) * 1991-11-04 1993-06-07 Novo Nordisk A/S Pdgf gel formulation
WO2001098325A1 (en) * 2000-06-19 2001-12-27 University Of Southern California Methods for treating and preventing alopecia
US20060058238A1 (en) 2004-09-15 2006-03-16 Lee Laurent-Applegate Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
EP2245061A2 (en) * 2007-12-11 2010-11-03 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
KR101514414B1 (ko) * 2011-02-02 2015-05-04 유니버시티 오브 써던 캘리포니아 당뇨병성 족부 궤양의 치료방법

Patent Citations (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015629A (en) 1989-06-26 1991-05-14 University Of Southern California Tissue repair
US6096709A (en) 1993-09-24 2000-08-01 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
US5629292A (en) 1993-09-24 1997-05-13 The University Of Southern California Use of angiotensin III and analogs thereof in tissue repair
US5716935A (en) 1993-09-24 1998-02-10 University Of Southern California Use of antiotensin II analogs in tissue repair
US5955430A (en) 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
US6444646B1 (en) 1995-06-06 2002-09-03 University Of Southern California Use of angiotensin II type 2 receptor agonists in tissue repair
US5834432A (en) 1995-06-06 1998-11-10 The University Of Southern California Use of angiotensin II Type 2 receptor agonists in tissue repair
US6110895A (en) 1996-12-16 2000-08-29 University Of Southern California Method of promoting healing in skin grafts
US7118748B1 (en) 1997-01-28 2006-10-10 University Of Southern California Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US6335195B1 (en) 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US7744927B2 (en) 1997-01-28 2010-06-29 University Of Southern California Methods of promoting hematopoietic and mesenchymal cell proliferation and differentiation
WO1998033813A2 (en) 1997-02-04 1998-08-06 University Of Southern California Method for accelerating healing of thermal injuries
US6248587B1 (en) 1997-11-26 2001-06-19 University Of Southern Cailfornia Method for promoting mesenchymal stem and lineage-specific cell proliferation
US7022675B2 (en) 1997-12-12 2006-04-04 University Of Southern California Wound healing compositions
WO1999031125A1 (en) 1997-12-12 1999-06-24 University Of Southern California Wound healing compositions
US6455501B1 (en) 1997-12-12 2002-09-24 University Of Southern California Wound healing compositions
US6165978A (en) 1997-12-12 2000-12-26 University Of Southern California Wound healing composition
WO1999040107A2 (en) 1998-02-09 1999-08-12 University Of Southern California Method of promoting keratinocyte proliferation
US7776828B2 (en) 1998-03-10 2010-08-17 University Of Southern California Radiation therapy methods
US6455500B1 (en) 1998-03-10 2002-09-24 University Of Southern California Radiation therapy methods
US6498138B1 (en) 1998-03-11 2002-12-24 University Of Southern California Method of promoting production of living tissue equivalents
US6475988B1 (en) 1998-05-11 2002-11-05 University Of Southern California Methods to increase white blood cell survival after chemotherapy
US6566335B1 (en) 1998-05-11 2003-05-20 University Of Southern California Methods for mobilizing hematopoietic progenitor cells from bone marrow into peripheral blood in a patient in need of chemotherapy
US6762167B1 (en) 1998-05-11 2004-07-13 University Of Southern California Methods for treating a patient undergoing chemotherapy
US6916783B2 (en) 1998-07-13 2005-07-12 University Of Southern California Methods for accelerating bone and cartilage growth and repair
US6258778B1 (en) 1998-07-13 2001-07-10 University Of Southern California Methods for accelerating bone and cartilage growth and repair
US6482800B1 (en) 1998-08-13 2002-11-19 The University Of Southern California Methods to stimulate angiogenesis
US6177407B1 (en) 1998-08-13 2001-01-23 University Of Southern California Methods to increase blood flow to ischemic tissue
US6730775B1 (en) 1999-03-23 2004-05-04 University Of Southern California Methods for limiting scar and adhesion formation
US7338938B2 (en) 1999-05-10 2008-03-04 University Of Southern California Methods for treating a patient undergoing chemotherapy
US7786085B2 (en) 1999-05-10 2010-08-31 University Of Southern California Method for treating a patient undergoing chemotherapy
US6821953B1 (en) 1999-12-16 2004-11-23 University Of Southern California Methods for treating and preventing damage to mucosal tissue
US7176183B2 (en) 1999-12-16 2007-02-13 University Of Southern California Methods for treating and preventing damage to mucosal tissue
WO2001044270A2 (en) 1999-12-16 2001-06-21 University Of Southern California Methods for treating and preventing diabetic complications by use of angiotensin-related peptides
US7173011B2 (en) 2000-11-20 2007-02-06 University Of Southern California Radiation therapy methods
US20090227507A1 (en) 2008-03-10 2009-09-10 University Of Southern California Angiotensin (1-7) Dosage Forms and Uses Thereof
WO2011120032A1 (en) 2010-03-26 2011-09-29 University Of Southern California Methods for treating combined radiation and thermal injury
WO2012021578A1 (en) 2010-08-10 2012-02-16 University Of Southern California Use of angiotensin- ii (1-7) in cell trans planation and as an agent for preventing/treating norovirus infection

Non-Patent Citations (30)

* Cited by examiner, † Cited by third party
Title
American Diabetes Association, Consensus development conference on diabetic foot wound care. Diabetes Care 1999; 22:1354-1360.
Bolton L, McNees P, van Rijswijk L et al. Wound healing outcomes using standardized care. JWOCN 2004; 31:65-71.
Chappell MC, Jacobsen DW, Tallant EA. Characterization of angiotensin II receptor subtypes in pancreatic acinar AR42J cells. Peptides 1995; 16:741-747.
Chappell MC, Tallant EA, Brosnihan KB, Ferrario CM. Conversion of angiotensin I to angiotensin-(1-7) by thimet oligopeptidase (E.C.3.4.24.15) in vascular smooth muscle cells. J Vasc Biol Med 1995; 5:129-137.
Chappell MC, Tallant EA, Brosnihan KB, Ferrario CM. Processing of angiotensin peptides by NG108-15 neuroblastoma X glioma hybrid cell line. Peptides 1990; 22:375-380.
Daemen MJAP, Lombardi DM, Bosman FT, Schwartz SM.. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991; 68:450-56.
Dzau VE, Pratt R, Gibbons G, Schunkert H, Lorell B, Ingelfinger J. Molecular mechanism of angiotensin in the regulation of vascular and cardiac growth. J Mol Cell Cardiol 1989; 21 [Suppl III]:S7.
Foster AV, Eaton C, McConville DO, Edmonds ME. Application of OpSite film: a new and effective treatment of painful diabetic neuropathy. Diabetes Med 1994; 11(8):768-772.
Kawahara Y, Sunako M, Tsuda T, Fukazaki H, Fukomoto Y, Takai Y. Angiotensin II induces expression of the c-fos gene through protein kinase C activation and calcium ion mobilization in cultured vascular smooth muscle cells. BBRC 1988; 150:52-9.
Koibuchi Y, Lee WS, Gibbons GH, Pratt RE. Role of transforming growth factor B-1 in the cellular growth response to Angiotensin II. Hypertension 1993; 21:1046-50.
Mangiarua EI, Palmer VL, Lloyd LL, McCumbee WD. Platelet-derived growth factor mediates angiotensin II-induced DNA synthesis in vascular smooth muscle cells. Arch Physiol Biochem 1997; 105(2):151-7.
Naftilan AJ, Pratt RE, Dzau VJ. Induction of platelet-derived growth factor A-chain and c-myc gene expression by Angiotensin II in culture rat vascular smooth muscle cells. J Clin Invest 1989; 83:1419-24.
Okuyama N, Roda N, Guerrero A, Dougherty W, Nguyen T, diZerega GS, Rodgers KE. Effect of angiotensin II on the viability, vascularity of random flaps in a rat model. Annals Plastic Surgery Res 1999; 68:913-918.
Pecoraro RE, Reiber GE, Burgess EM, Pathways to diabetic limb amputation: basis for prevention. Diabetes Care 1990; 13:513-521.
Rodgers K, Xiong S, Felix J, Roda N, Espinoza T, Maldonado S, diZerega GS. Development of angiotensin (1-7) as an agent to accelerate dermal repair. Wound Repair Regen 2001; 9:238-250.
Rodgers KE, Ellefson DD, Espinoza T, Roda N, Maldonado S, diZerega GS. Effect of NorLeu3-A (1-7) on scar formation over time after full thickness incision injury in the rat. Wound Repair Regen 2005; 13:309-317.
Rodgers KE, Espinoza T, Felix J, Roda N, Maldonado S, diZerega GS. Acceleration of healing, reduction of fibrotic scar, and normalization of tissue architecture by an angiotensin analogue, Norleu3-A (1-7). Plast Reconstr Surg 2003; 111:1195-1206.
Rodgers KE, Roda N, Felix JC, Espinoza T, Maldonado S, diZerega GS. Histological evaluation of the effects of angiotensin peptides on wound repair in diabetic mice. Experimental Dermatology 2003; 12(6):784-790.
Rodgers LC. Driver VR, Armstrong DG. Assessment of the diabetic foot. In Krasner DL, Rodeheaver GT, Sibbald RG eds. Chronic Wound Care: A Clinical Source Book for Healthcare Professionals. 4th ed. Malvern PA: HMP Communications, 2007: 549-556.
Rodgers, et al., (2006) J. Peptide Res., 66(suppl. 1):41-47.
Rodgers, KE, Abiko M, Girgis W, St. Amand KM, Campeau JD, diZerega GS. Acceleration of dermal tissue repair by Angiotensin II. Wound Repair Regen 1997; 5:175-183.
Rodgers, KE, DeCherney AH, St. Amand KM, Dougherty WR, Felix JC, Girgis W, diZerega GS. Histologic alterations in dermal repair after thermal injury: effects of topical angiotensin II. Burn Care and Rehabilitation 1997; 18:381-388.
Santos et al. Characterization of a new angiotensin antagonist selective for angiotensin-(1-7): evidence that the actions of angiotensin-(1-7) are mediated by specific angiotensin receptors. Brain Res Bull 1994; 35:293-298.
Santos RAS, Brosnihan KB, Jacobsen DW, DiCorleto P, and Ferrario CM. Production of Ang-(1-7) by human vascular endothelium. Hypertension 1992; 19(suppl II):II-56-II-61.
Santos RS, Brosnihan KB, Chappell MC, Pesquero J, Chernicky CL, Greene LJ, and Ferrario CM. Converting enzyme activity and angiotensin metabolism in the dog brainstem. Hypertension 1988; 11(suppl I):I-53-I-57.
Sheehan P, Jones P, Caselli A, Giurini JM, Veves A. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care 2003; 26:1879-1882.
Stouffer GA, Owens GK. Angiotensin II induced mitogenesis of spontaneously hypertensive rat derived cultured smooth muscle cells is dependent on autocrine production of transforming growth factor-B. Circ Res 1992; 70:820-28.
Su EJ, Lombardi DM, Wiener J, Daemen MJ, Reidy MA, and Schwartz MA. Mitogenic effect of angiotensin II on the rat carotid arteries and type II or III mesenteric microvessels but not type I mesenteric microvessels is mediated by endogenous basic fibroblast growth factor. Circ Res 1998; 82:321.
Wagner, FJ. A classification and treatment program for diabetic, neuropathic, and dysvascular foot problems. Am Acad of Orthopaedic Surgeons. Instructional Course Lecture 1979; 28:143-165.
Yamamoto K, Chappell MC, Brosnihan KB, Ferrario CM. In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension 1992; 19:692-696.

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120329729A1 (en) * 2011-02-02 2012-12-27 University Of Southern California Methods for treating diabetic foot ulcers
US8536231B2 (en) * 2011-02-02 2013-09-17 Kathleen E. Rodgers Methods for treating diabetic foot ulcers
US9688724B2 (en) 2012-05-14 2017-06-27 University Of Southern California Methods for limiting development of a skin wound
WO2014043693A1 (en) * 2012-09-17 2014-03-20 Tarix Pharmaceuticals Ltd. Oral formulations of angiotensin
US9623084B2 (en) 2013-03-15 2017-04-18 University Of Southern California Methods for treating multiple sclerosis
US9732074B2 (en) 2013-03-15 2017-08-15 University Of Southern California Methods, compounds, and compositions for the treatment of angiotensin-related diseases
US10301298B2 (en) 2013-03-15 2019-05-28 University Of Southern California Methods, compounds, and compositions for the treatment of angiotensin-related diseases

Also Published As

Publication number Publication date
AU2012212220A1 (en) 2012-10-18
PL2536422T3 (pl) 2014-09-30
WO2012106427A2 (en) 2012-08-09
CL2012002560A1 (es) 2013-03-22
CN102858360B (zh) 2017-07-25
KR101514414B1 (ko) 2015-05-04
KR20120137365A (ko) 2012-12-20
JP5469777B2 (ja) 2014-04-16
WO2012106427A3 (en) 2012-09-20
US8207234B1 (en) 2012-06-26
AU2012212220B2 (en) 2013-04-04
EA201201296A1 (ru) 2013-02-28
CA2793515C (en) 2015-05-12
HK1180213A1 (en) 2013-10-18
PE20130379A1 (es) 2013-04-13
US8536231B2 (en) 2013-09-17
JP2013523781A (ja) 2013-06-17
ES2479765T3 (es) 2014-07-24
CN102858360A (zh) 2013-01-02
PT2536422E (pt) 2014-07-18
US20120329729A1 (en) 2012-12-27
CO6592101A2 (es) 2013-01-02
SG183960A1 (en) 2012-10-30
ZA201207340B (en) 2013-02-27
EP2536422B1 (en) 2014-04-30
DK2536422T3 (da) 2014-07-28
EP2536422A2 (en) 2012-12-26
EA026440B1 (ru) 2017-04-28
CA2793515A1 (en) 2012-08-09
JP2014080425A (ja) 2014-05-08
MX2012010783A (es) 2012-11-23
EP2536422B8 (en) 2023-06-21
BR112013019513A2 (pt) 2019-06-11

Similar Documents

Publication Publication Date Title
US8207234B1 (en) Methods for treating diabetic foot ulcers
JP5435955B2 (ja) 安定な酵素製剤及びその使用方法
KR102360938B1 (ko) 새로운 만성 궤양 치료제
DK2222327T3 (en) TOPICAL USE AND FORMULATION OF ERYTHROPOIETIN FOR HEALTH CARE
US20050181028A1 (en) Topical composition and method for treating occlusive wounds
JP4192093B2 (ja) 慢性皮膚潰瘍の治癒を促進する方法
US20110077218A1 (en) Wound-healing pharmaceutical compositions in the form of a sterile powder based on amino acids and sodium hyaluronate
EP1364645A1 (en) Pharmaceutical combinations for topical use based on iron chelators, metalloprotease inhibitors and factor XIII for the treatment of lipodermatosclerosis and trophic lesions of the cutaneous tissues and muccous membranes
JP2002518417A (ja) 勃起機能不全の治療装具及び方法
AU2012244179B2 (en) Methods for treating diabetic foot ulcers
CN112316108B (zh) 促进及治疗慢性伤口愈合的组合物和方法
DE60017793T2 (de) Verfahren zur vorbeugung und behandlung von beschädigungen des schleimhautgewebes
Helmke Current topical treatments in wound healing: part 1
Canter Conservative management of wounds
JP2023552515A (ja) 創傷を治療するための組成物および方法
JP2022525935A (ja) 糖尿病性足部潰瘍の治療における上皮細胞増殖因子の使用
Stegbauer Enhanced wound healing using topical recominant human platelet-derived growth factor
WO2019125577A1 (en) Method of treatment of diabetic foot ulcers
Naveen Clinicopathological Study, Management of Diabetic Foot and Its Complications
JP2004026808A (ja) 痔疾治療剤
JPH04145019A (ja) 塩化リゾチーム含有貼付剤

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 8

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2553); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 12